{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    12,
    13,
    14,
    15,
    16,
    18,
    22,
    24,
    26
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Safety Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.6",
        "sectionTitle": "Lymphocytosis and Leukostasis",
        "description": "Updated safety information to align with the current Investigator’s Brochure"
      },
      {
        "id": "ref_2",
        "name": "Safety Update Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.7",
        "sectionTitle": "Clinical Safety of Ibrutinib",
        "description": "Updated safety information to align with the current Investigator’s Brochure"
      },
      {
        "id": "ref_3",
        "name": "Vital Signs Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5",
        "sectionTitle": "Safety Evaluations",
        "description": "Additional pulse/heart rate and blood pressure assessments added"
      },
      {
        "id": "ref_4",
        "name": "Clinical Cutoff Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1.5",
        "sectionTitle": "Clinical Cutoffs",
        "description": "Reports of new malignancies added to data collection after final analysis of PFS"
      },
      {
        "id": "ref_5",
        "name": "Concomitant Medication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Precautions with Concomitant Medications",
        "description": "Updated external links for classification of CYP3A inhibitors and inducers"
      },
      {
        "id": "ref_6",
        "name": "Hepatic Impairment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.4.3.1",
        "sectionTitle": "Dose Modification for Subjects With Chronic Hepatic Impairment",
        "description": "Instructions for dose modification based on Child-Pugh class A, B, or C"
      },
      {
        "id": "ref_7",
        "name": "Attachment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Attachment 4",
        "sectionTitle": "Inhibitors and Inducers of CYP3A",
        "description": "Updated external links for classification of CYP3A inhibitors and inducers"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries. The legal entity acting as the sponsor may vary.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "Vital sign assessments should be recorded in source documents but will not be routinely collected in the eCRF.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 1, Time and Events Schedule",
        "pageNumber": 6
      },
      {
        "id": "annot_3",
        "text": "Blood samples for the assessment of CR MRD will no longer be collected except in subjects whose first assessment of CR is after the issue date of this amendment.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Amendment INT-6",
        "pageNumber": 7
      },
      {
        "id": "annot_4",
        "text": "Review of systems should include inquiry of ocular symptoms (eg, dry eye, blurred vision). Subjects should be referred to an ophthalmologist for formal examination if Grade >= 2 symptoms are reported.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.5 Safety Evaluations",
        "pageNumber": 11
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment INT-7",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-12-19",
        "description": "Update safety information regarding cerebrovascular accidents and clarify vital sign monitoring.",
        "amendmentNumber": "7"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment INT-6",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-08-16",
        "description": "Halt collection of CR MRD samples for specific subjects.",
        "amendmentNumber": "6"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment INT-5",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-07-12",
        "description": "Clarify DMC recommendations and update hepatic impairment dose modifications.",
        "amendmentNumber": "5"
      },
      {
        "id": "ver_4",
        "versionNumber": "Original Protocol",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2012-12-20",
        "description": "Initial release of the clinical protocol.",
        "amendmentNumber": "0"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 4
    }
  }
}